Results 271 to 280 of about 68,932 (348)

Behind the scenes: how the EMILIN/Multimerin family shapes the cancer landscape

The FEBS Journal, Volume 293, Issue 13, Page 3991-4013, July 2026.
The EMILIN/Multimerin family members regulate key hallmarks of cancer—including apoptosis, angiogenesis, metastasis, and tumor microenvironment remodeling. As indicated, their function in immune evasion, drug resistance, and metabolic reprogramming remains largely unexplored.
Evelina Poletto, Naike Casagrande, Emanuele Di Siena, Greta Carobolante, Lucrezia Camicia, Giorgia Schinello, Samanta Muzzin, Enrica Timis, Paola Spessotto, Maurizio Mongiat   +9 more
wiley   +1 more source

Targeting the microbiota‐miRNA‐protease axis: A new therapeutic avenue in melanoma

The FEBS Journal, Volume 293, Issue 13, Page 4043-4063, July 2026.
Modulation of extracellular matrix (ECM) turnover is central to melanoma progression and metastasis, driven largely by ECM proteases. This review highlights the epigenetic regulation of ECM proteases by microRNAs and their roles in melanoma growth, invasion, and immune modulation.
Elias N. Katsoulieris, Paraskevi Ioannou, Nikolaos A. Afratis   +2 more
wiley   +1 more source

Proteolysis at the extracellular matrix interface: Molecular architects and regulators in health and disease

The FEBS Journal, Volume 293, Issue 13, Page 3758-3787, July 2026.
The extracellular matrix (ECM) is a dynamic scaffold that orchestrates tissue architecture and cellular communication. A critical but underexplored interplay between proteases and cluster of differentiation molecules (CD) governs ECM turnover and directs cell fate.
David Jurnečka, Matija Hrovatin, Bor Bokalj, Boris Turk   +3 more
wiley   +1 more source

Atypical Melanosis on Acral Skin or Early Acral Lentiginous Melanoma? Reappraising an Ambiguous Concept in Acquired Acral Pigmented Lesions

Journal of Cutaneous Pathology, Volume 53, Issue 7, Page 648-654, July 2026.
Marcial Álvarez‐Salafranca, Pedro Gil‐Pallares, Alba Navarro‐Bielsa, Tamara Gracia‐Cazaña, Carlos Monteagudo, María Carmen Gómez‐Mateo   +5 more
wiley   +1 more source

Molecular classification of cutaneous malignant melanoma by gene expression profiling

Nature, 2000
The most common human cancers are malignant neoplasms of the skin(1,2). Incidence of cutaneous melanoma is rising especially steeply, with minimal progress in non-surgical treatment of advanced disease(3,4).
M. Bittner, P. S. Meltzer, Yidong Chen, Yong Jiang, E. Seftor, M. Hendrix, M. Radmacher, R. Simon, Z. Yakhini, A. Ben-Dor, N. Sampas, E. Dougherty, E. Wang, F. Marincola, C. Gooden, J. Lueders, A. Glatfelter, Pamela M. Pollock, J. Carpten, E. Gillanders, D. Leja, K. Dietrich, C. Beaudry, M. Berens, D. Alberts, V. Sondak   +25 more
semanticscholar   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Cutaneous malignant melanoma

Journal of the American Academy of Dermatology, 1991
C UTANEOUS MALIGNANT melanoma (CMM) is a cancer that arises in the melanin-producing cells called melanocytes. It is one of the most easily detected cancers, as the patient usually presents with a skin lesion that is readily visible. Melanomas that are detected early are almost always curable by surgical excision.’ With this in mind, the importance of ...
C, Grin-Jorgenson, A W, Kopf, J C, Maize
openaire   +4 more sources

Cutaneous Malignant Melanoma

Clinical Obstetrics and Gynecology, 2002
Melanoma is the deadliest form of skin cancer; 47,700 persons were expected to be diagnosed and 9,600 were expected to die from melanoma in 2000 (American Cancer Society, 2000). It is important for dermatology nurses to understand the epidemiology, risk factors, clinical presentation, diagnosis, treatment, prognosis, and prevention of cutaneous ...
Edward, Podczaski, Joanna, Cain
openaire   +4 more sources

Cutaneous Malignant Melanoma

Handbook of Tumor Syndromes, 2020
Dongyou Liu
openaire   +2 more sources

Potential diagnostic utility of PRAME and p16 immunohistochemistry in melanocytic nevi and malignant melanoma

Journal of cutaneous pathology, 2023
PRAME (PReferentially expressed Antigen in MElanoma) is a tumor‐associated antigen that has been studied in various cutaneous melanocytic lesions. p16, on the other hand, has been proposed to aid in distinguishing between benign and malignant melanocytic
H. Bahmad, K. Oh, J. Alexis
semanticscholar   +1 more source